heart ECG News
-
MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Sites All Using Meridian™ Fetal ECG Research Device
The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes (North Andover, Massachusetts), MindChild Medical, Inc. today announced it has shipped 24 Meridian M110R Fetal Research Devices and 8,000 electrode patch sets to the UNC LABOR Study’s sites in ...
-
MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Enrolls 6,000th Subject Recorded with Meridian™ Fetal ECG Research Device
The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes (North Andover, Massachusetts), Mindchild Medical, Inc. announced that the LABOR study recorded its 6,000th subject with MindChild’s Meridian Fetal Research Device. Jay Ward, MindChild Medical’s ...
-
HD Medical Wins Coveted Award from Silicon Valley Open Doors (SVOD) Technology Investment Conference
HD Medical, Inc. of Santa Clara, CA today announces it has been awarded First Runner-up in the Silicon Valley Open Doors Technology Investment Pitch Competition. The company reviewed the impact of how its innovative new ECG-enabled intelligent stethoscope, HD Steth™, is saving lives through HD Medical’s Screening as a Service (SaaS) business model. “We awarded HD Medical ...
-
Michael Herring Joins HD Medical as US Vice President of Sales
HD Medical, Inc., the leader in cardiovascular disease detection, today announces that Michael Herring has joined the team as the US Vice President of Sales. Herring brings his 25 years of experience in medical device sales to the company, having previously worked for 3M, Cantel Medical, Nanosonics, and TSO3. Herring plans to leverage his unique background in medical device sales management and ...
-
Biotricity now taking pre-orders for its Biotres wireless wearable cardiac monitoring device
Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record ...
-
Biotricity wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with ...
-
Biotricity receives FDA 510(k) clearance for its Biotres Cardiac Monitoring Device
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Drug ...
-
VUNO Med-DeepECG Designated as Breakthrough Device
South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company’s artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™ as the ministry’s 16th Breakthrough Device. Using deep learning, the software analyzes ECG data to zero in on heart failure, ...
By Vuno Inc.
-
Bardy Diagnostics Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine
Seattle, WA — March 25, 2020 — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that its Carnation Ambulatory Monitor (“CAM™”) Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine ...
-
Coala Life in collaboration with Region Gävleborg, Sweden, to run the TITAN-DM study on 500 patients with diabetes
Stockholm, October 7, 2021: Coala Life, a leading company in cloud-based remote monitoring of heart and lung diseases, is now conducting a clinical observational study in collaboration with researchers at the Gävleborg Region, Uppsala University and Karolinska Institute to increase knowledge about the incidence of atrial fibrillation in people with diabetes. The TITAN-DM study is expected to ...
-
Vektor Medical to Present Positive Results from vMap Clinical Validation Study Showing 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias
Non-invasive arrhythmia technology maps using only the data from a 12 lead ECG vMap provides actionable mapping results in minutes. Blinded, multi-center study with analysis by an independent core laboratory Results to be presented for the first time at Heart Rhythm 2022 Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation ...
-
Bardy Diagnostics Announces CE Mark Certification for 14-Day Carnation Ambulatory Monitor (CAM™) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis
SEATTLE, May 26, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received CE mark certification for the 14-Day version of the Carnation Ambulatory Monitor (“CAM”) patch, the industry’s only P-wave centric ambulatory cardiac patch monitor and ...
-
Vektor Medical receives FDA clearance for vMAP, First Technology designed to identify arrhythmia hot spots anywhere in heart in minutes using only ECG data
Vektor Medical, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel computational ECG mapping system, vMap™. vMap is designed to map potential arrhythmia sources (hot spots) associated with stable or unstable arrhythmias anywhere in the heart – including all four chambers, the septal wall, and the outflow tracts – in less than three ...
-
Professor Gust H. Bardy, M.D. of Bardy Diagnostics Partners with Arrhythmia Alliance to Increase Patient Awareness of Heart Arrhythmias and Early Detection
(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...
-
Q&A with Dr. Carina Carnlöf, lead investigator of the RedHeart study
In the recently published RedHeart Study the Coala Heart Monitor was used to remotely monitor 821 women with palpitation issues for 60 days. Over 200,000 individual ECG strips were analyzed. The direct ECG response of the Coala Heart Monitor contributed to reduced levels of anxiety, depression and symptoms of palpitations. The direct ECG response of the Coala also led to an increased quality of ...
-
ams introduces sensor reference design for blood pressure, vital signs for smart health and wearables
ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, today announced the release of the first integrated vital sign sensor reference design based on its AS7024.The solution can perform accurate, fast and convenient 24/7 cuffless blood pressure measurement. The new vital signs sensor reference design based on AS7024 integrates all the hardware components, including ...
By ams-OSRAM AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you